Valuation: Tengion, Inc.

Market Cap 110K 96.79K 91.55K 82.98K 156K 10.53M 157K 1.09M 422K 5.38M 412K 403K 17.27M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.9M 4.63M 4.2M 7.88M 533M 7.95M 55.37M 21.36M 272M 20.85M 20.39M 874M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
1 day+900.00%
3 months+900.00%
6 months+900.00%
Current year+900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.02
10 years 0
Extreme 1.0E-6
0.04
Change 5-day change 1-year change 3-year change Capi.($)
+900.00%-.--%+900.00%-.--% 402
+1.86%-7.02% - - 1.19B
-0.21%-2.91%-32.71%-38.39% 682M
-6.32%-6.96%+27.44% - 373M
-0.84%+3.23%-50.94%-25.76% 129M
-1.08%-8.04%-20.09%+12.96% 70.24M
Average +148.90%+147.59%+164.74%-12.80% 407.06M
Weighted average by Cap. -0.20%-4.94%-15.99%-32.45%

Financials

2012 2013
Net sales - -
Net income -16.93M -14.93M -14.12M -12.8M -24.02M -1.62B -24.24M -169M -65.13M -829M -63.57M -62.18M -2.66B -18.93M -16.69M -15.79M -14.31M -26.86M -1.82B -27.1M -189M -72.82M -927M -71.07M -69.52M -2.98B
Net Debt 3.73M 3.29M 3.11M 2.82M 5.3M 358M 5.34M 37.23M 14.36M 183M 14.02M 13.71M 587M 5.44M 4.8M 4.54M 4.11M 7.72M 522M 7.79M 54.28M 20.94M 267M 20.43M 19.99M 856M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
26
  1. Stock Market
  2. Stocks
  3. TNGNQ Stock